Headquartered in London, AIM-listed Immupharma has a research facility located in France.
Scientists and researchers at Immupharma are dedicated to the development of innovative drugs designed to treat serious medical conditions, with a focus on developing novel medicines for specialist markets (such as lupus).
BDB Pitmans team was led by corporate partner Philip Lamb with support from senior associate Mireille Turner.
Tim McCarthy, Chairman and CEO of ImmuPharma, commented: “We are entering a transitional period for ImmuPharma, as we seek to begin the international phase 3 clinical trials of Lupuzor™ with our partner, Avion Pharmaceuticals, with a long-term view to licensing the product in key territories outside of the US. We would like to take this opportunity to thank BDB Pitmans for their invaluable guidance and excellent client service.”
Philip Lamb concluded: “ImmuPharma are at the cutting edge of pharmaceutical development and it was a pleasure to support a company working to make a life changing difference to thousands of people worldwide. We have no doubt that the fundraising at this stage will help Immupharma to strengthen its position, diversify its offering and uncover further opportunities for growth.”
